Literature DB >> 1412462

A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat.

D R Plowchalk1, M E Andersen, J D deBethizy.   

Abstract

A physiologically based pharmacokinetic (PBPK) model was developed to describe the disposition of nicotine in the Sprague-Dawley (SD) rat. Parameters for the model were either obtained from the literature (blood flows, organ volumes) or determined experimentally (partition coefficients). Nicotine metabolism was defined in the liver compartment by the first-order rate constants KNC and KNP which control the rate of nicotine metabolism to cotinine and "polar metabolites" (PM), respectively. These rate constants were estimated by optimizing the model fit to pharmacokinetic data obtained by administering an intraarterial (S)-[5-3H]nicotine bolus of 0.1 mg/kg to 6 rats. Model simulations that optimized for the appearance of cotinine in plasma estimated KNC and KNP to be 75.8 and 24.3 hr-1, respectively. Use of these constants in the model allowed us to accurately predict nicotine plasma kinetics and the fraction of the dose eliminated by renal (8.5%) and metabolic (91.5%) clearance. To validate the model's ability to predict tissue kinetics of nicotine, 21 male SD rats were administered 0.1 mg/kg (S)-[5-3H]nicotine intraarterially. At seven time points following treatment, 3 rats were euthanized and tissues were removed and analyzed for nicotine. Model-predicted nicotine tissue kinetics were in agreement with those determined experimentally in muscle, liver, skin, fat, and kidney. The brain, heart, and lung exhibited nonlinear nicotine elimination, suggesting that saturable nicotinic binding sites may be important in nicotine disposition in these organs. Inclusion of saturable receptor binding expressions in the mathematical description of these compartments resulted in better agreement with the experimental data. The Bmax and KD estimated by model simulations for these tissues were brain, 0.009 and 0.12; lung, 0.039 and 2.0; and heart, 0.039 nmol/tissue and 0.12 nM, respectively. This PBPK model can successfully describe the tissue and plasma kinetics of nicotine in the SD rat and will be a useful tool for pharmacologic studies in humans and experimental animals that require insight into the plasma or tissue concentration-effect relationship.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412462     DOI: 10.1016/0041-008x(92)90297-6

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  15 in total

1.  Prediction of in vivo tissue distribution from in vitro data. 2. Influence of albumin diffusion from tissue pieces during an in vitro incubation on estimated tissue-to-unbound plasma partition coefficients (Kpu).

Authors:  Peter Ballard; Philip A Arundel; David E Leahy; Malcolm Rowland
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

2.  Prenatal nicotine exposure increases apnoea and reduces nicotinic potentiation of hypoglossal inspiratory output in mice.

Authors:  Dean M Robinson; Karen C Peebles; Henry Kwok; Brandon M Adams; Lan-Ling Clarke; Gerald A Woollard; Gregory D Funk
Journal:  J Physiol       Date:  2002-02-01       Impact factor: 5.182

3.  Nicotine is more efficient than cotinine at passing the blood-brain barrier in rats.

Authors:  O Riah; P Courrière; J C Dousset; N Todeschi; C Labat
Journal:  Cell Mol Neurobiol       Date:  1998-06       Impact factor: 5.046

4.  A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.

Authors:  Kyle Saylor; Chenming Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2016-07-26       Impact factor: 4.219

5.  Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling.

Authors:  Anna H C Vlot; Wilhelmus E A de Witte; Meindert Danhof; Piet H van der Graaf; Gerard J P van Westen; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

6.  Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis.

Authors:  Mathilde Marchand; Patrick Brossard; Henri Merdjan; Nicola Lama; Rolf Weitkunat; Frank Lüdicke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

7.  Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.

Authors:  Evelyn L Craig; Bin Zhao; Jason Z Cui; Maria Novalen; Sharon Miksys; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-06-30       Impact factor: 3.922

8.  Ibogaine and the dopaminergic response to nicotine.

Authors:  I M Maisonneuve; G L Mann; C R Deibel; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

9.  Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.

Authors:  Hiroshi Yamazaki; Kana Horiuchi; Ryohji Takano; Taku Nagano; Makiko Shimizu; Masato Kitajima; Norie Murayama; Fumiaki Shono
Journal:  Int J Environ Res Public Health       Date:  2010-09-01       Impact factor: 3.390

10.  Perinatal Nicotine Reduces Chemosensitivity of Medullary 5-HT Neurons after Maturation in Culture.

Authors:  Joanne Avraam; Yuanming Wu; George Bradley Richerson
Journal:  Neuroscience       Date:  2020-08-17       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.